MDGL Madrigal Pharmaceuticals Inc

Price (delayed)

$80.15

Market cap

$1.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.61

Enterprise value

$1.3B

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum ...

Highlights
The equity is down by 21% year-on-year but it is up by 3.9% since the previous quarter
The debt has surged by 92% year-on-year and by 41% since the previous quarter
The company's net income has shrunk by 72% YoY and by 6% QoQ

Key stats

What are the main financial stats of MDGL
Market
Shares outstanding
16.6M
Market cap
$1.33B
Enterprise value
$1.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$231.28M
EBITDA
-$230.85M
Free cash flow
-$193.17M
Per share
EPS
-$14.61
Free cash flow per share
-$11.66
Book value per share
$16.32
Revenue per share
$0
TBVPS
$19.79
Balance sheet
Total assets
$327.96M
Total liabilities
$57.3M
Debt
$997,000
Equity
$270.65M
Working capital
$269.36M
Liquidity
Debt to equity
0
Current ratio
5.75
Quick ratio
5.71
Net debt/EBITDA
0.14
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-73.2%
Return on equity
-87.2%
Return on invested capital
-112.1%
Return on capital employed
-85.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MDGL stock price

How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
0.97%
1 week
0.05%
1 month
-3.33%
1 year
-26.14%
YTD
-27.9%
QTD
-17.72%

Financial performance

How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$233.06M
Net income
-$231.28M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 72% YoY and by 6% QoQ
MDGL's operating income has shrunk by 64% YoY and by 5% QoQ

Growth

What is Madrigal Pharmaceuticals's growth rate over time

Valuation

What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 68% YoY and by 3.8% from the previous quarter
The stock's price to book (P/B) is 27% less than its last 4 quarters average of 6.7 and 9% less than its 5-year quarterly average of 5.4
The equity is down by 21% year-on-year but it is up by 3.9% since the previous quarter

Efficiency

How efficient is Madrigal Pharmaceuticals business performance
Madrigal Pharmaceuticals's ROIC has plunged by 176% YoY and by 11% from the previous quarter
The ROE has plunged by 157% YoY and by 13% from the previous quarter
MDGL's return on assets has dropped by 132% year-on-year and by 11% since the previous quarter

Dividends

What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDGL.

Financial health

How did Madrigal Pharmaceuticals financials performed over time
The company's quick ratio fell by 33% YoY and by 9% QoQ
The current ratio has declined by 33% year-on-year and by 9% since the previous quarter
The debt is 100% smaller than the equity
The debt has surged by 92% year-on-year and by 41% since the previous quarter
The equity is down by 21% year-on-year but it is up by 3.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.